<DOC>
	<DOC>NCT00585312</DOC>
	<brief_summary>To test whether celecoxib can be used to prevent colon polyp formation in children with familial adenomatous polyposis (FAP).</brief_summary>
	<brief_title>Trial In Pediatric Patients With Familial Adenomatous Polyposis (FAP)</brief_title>
	<detailed_description>Per DMC recommendation, the study was terminated early (31Oct2013) due to low enrollment and low endpoint accumulation rate. No safety concerns were involved in the decision to terminate the study.</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Adenomatous Polyposis Coli</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>Age 1017 years Confirmed deleterious FAP genotype based on central genetic testing or personal history ot &gt;2 colorectal adenomas and a parent with the diagnosis of FAP and either A, B or C below A: Nonattenuated FAP genotype B: Attenuated FAP genotype and a personal history of colorectal adenomas and a first degree relative with FAP C: No genotype identified with a personal history of &gt; 2 adenomas and have a parent with FAP Less than 30 polyps, which need to be removed to render the colon polypfree before study drug can be given Diagnosis of attenuated FAP based on central genetic testing in the absence of a personal history of &gt;2 colorectal adenomas and a first degree relative (parent or sibling) with FAP. Sensitivity to COX2 inhibitors</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>FAP</keyword>
</DOC>